

6 March 2026

Treatment of Cancers

The questions below in relation to the number of patients treated with specific medicines between the start of October 2025 to the end of December 2025, or the latest three-month period for which data is available. Please include data for all hospitals in the Health and Social Care Trust.

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	42
1.2 Alpelisib (Piqray)	0
1.3 Elacestrant (Orserdu)	0
1.4 Fulvestrant (fulvestrant or Faslodex)	26
1.5 Inavolisib (Inaqovi)	0
1.6 Palbociclib (Ibrance)	35
1.7 Ribociclib (Kisqali)	26
1.8 Capivasertib (Truqap)	5
1.9 Talazoparib (Talzenna)	<5
1.10 Olaparib (Lynparza)	25

Q2. How many patients received the following medicines for early breast cancer in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period for which data are available?

**early breast cancer information not available. This is not recorded by Belfast Trust.

Name of combination or monotherapy	Number patients treated
2.1 Abemaciclib (Verzenios)	All Breast Cancer - 42
2.2 Ribociclib (Kisqali)	All Breast Cancer - 26
2.3 Olaparib (Lynparza)	All Breast Cancer - <5

6 March 2026

Q3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period for which data are available?

This is not recorded by Belfast Trust

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios)	
3.2 Ribociclib (Kisqali)	

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period available?

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	<5
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	<5
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	<5

Q5. How many patients were treated specifically for breast cancer in the 3 months between the start of October 2025 and the end of December 2025?

Type of breast cancer	Number patients treated
5.1 Olaparib - All types of breast cancer	<5
5.2 Olaparib - Locally advanced or metastatic breast cancer	** Not available
5.3 Talazoparib – All types of breast cancer	<5

Q6. How many patients were treated in total with the following products in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
6.1 Pertuzumab (Perjeta)	0
6.2 Pertuzumab with Trastuzumab (Phesgo)	29
6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	33

6 March 2026

6.4 Trastuzumab Deruxtecan (EnHertu)	8
6.5 Trastuzumab Emtansine (Kadcyla)	7
6.6 Tucatinib (Tukysa)	<5
6.7 Neratinib (Nerlynx)	<5

Q7. How many patients were treated with the following products for a diagnosis of Breast Cancer (ICD-10 codes = C50*, D509) in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	21
7.2 Trastuzumab Deruxtecan (EnHertu)	8

Q8. How many patients received the following products with curative treatment intent in the 3 months between the start of October 2025 to the end of December 2025, or latest 3-month period for which data are available?

This is not recorded by Belfast Trust

Products	Number patients treated
8.1 Pertuzumab (Perjeta)	
8.2 Pertuzumab with Trastuzumab (Phesgo)	
8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab)	
8.4 Trastuzumab Emtansine (Kadcyla)	

Q9. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the start of October 2025 to the end of December 2025, or latest 3-month period for which data are available?

This is not recorded by Belfast Trust

6 March 2026

Products		Neoadjuvant	Adjuvant	Total Neo-adj or adjuvant
9.1 Pertuzumab (Perjeta)				
9.2 Pertuzumab with Trastuzumab (Phesgo)				
9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)				
9.4 Trastuzumab Emtansine (Kadcyla)				

Q10. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the start of October 2025 to the end of December 2025, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
10.1 HER2+ve Breast Cancer	6
10.2 HER2-low Breast Cancer	<5

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.